- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic treatment of solid tumours: a review of clinical trials
Authors
Keywords
Epigenetic treatment, Histone deacetylases (HDACs), Histone methyltransferases (HMTs), DNA methylation, DNA-methyltransferases, ncRNAs, Azacytidine, Decitabine, Valproic acid, Suberoylanilide hydroxamic acid (SAHA)
Journal
Clinical Epigenetics
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-12-13
DOI
10.1186/s13148-015-0157-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- lncRNAs and microRNAs with a role in cancer development
- (2016) Julia Liz et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
- (2015) S. Fu et al. ANNALS OF ONCOLOGY
- Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial
- (2015) John D. Hainsworth et al. CANCER
- Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
- (2015) Ji-Youn Han et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
- (2015) Rakesh Singal et al. Clinical Genitourinary Cancer
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
- (2015) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- RNA-mediated epigenetic regulation of gene expression
- (2015) Daniel Holoch et al. NATURE REVIEWS GENETICS
- Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
- (2014) S Bauer et al. BRITISH JOURNAL OF CANCER
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma
- (2014) Edwin Choy et al. CANCER
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
- (2014) Chang Xia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
- (2014) A. Thomas et al. CLINICAL CANCER RESEARCH
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
- (2014) J. E. Gray et al. CLINICAL CANCER RESEARCH
- Epigenetic alterations in acute myeloid leukemias
- (2014) Parinaz Mehdipour et al. FEBS Journal
- A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors
- (2014) Nuttapong Ngamphaiboon et al. INVESTIGATIONAL NEW DRUGS
- Phase II trial of vorinostat in advanced melanoma
- (2014) N. B. Haas et al. INVESTIGATIONAL NEW DRUGS
- Three Cheers for Targeted Therapy in Non-Small Cell Lung Cancer… When We Hit the Target!
- (2014) G. Codacci-Pisanelli et al. JOURNAL OF CHEMOTHERAPY
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
- (2014) Noemi Reguart et al. LUNG CANCER
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- DNA methylation markers for early detection of women’s cancer: promise and challenges
- (2014) Timo Wittenberger et al. Epigenomics
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
- (2013) P A Cassier et al. BRITISH JOURNAL OF CANCER
- Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
- (2013) Jill M. Kolesar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
- (2013) Dana E. Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
- (2013) A. T. Brunetto et al. CLINICAL CANCER RESEARCH
- Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer
- (2013) V. Stearns et al. CLINICAL CANCER RESEARCH
- Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
- (2013) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
- (2013) B. Venugopal et al. CLINICAL CANCER RESEARCH
- Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents
- (2013) Valeria Santini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Perspectives on the mechanism of transcriptional regulation by long non-coding RNAs
- (2013) Thomas C Roberts et al. Epigenetics
- Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I
- (2013) Sylvain Fouliard et al. EUROPEAN JOURNAL OF CANCER
- A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
- (2013) Dustin A. Deming et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
- (2013) William R. Schelman et al. INVESTIGATIONAL NEW DRUGS
- Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer
- (2013) Changhoon Yoo et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
- (2013) A. Newbold et al. MOLECULAR CANCER THERAPEUTICS
- Histone lysine demethylases as targets for anticancer therapy
- (2013) Jonas W. Højfeldt et al. NATURE REVIEWS DRUG DISCOVERY
- Epigenetic role of miRNAs in normal and leukemic hematopoiesis
- (2013) Francesca Pagano et al. Epigenomics
- Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
- (2013) Metin Karahoca et al. Clinical Epigenetics
- Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis
- (2012) H. A. Tawbi et al. ANNALS OF ONCOLOGY
- Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
- (2012) John H. Strickler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
- (2012) Sally Clive et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
- (2012) Suzanne F. Jones et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
- (2012) B. F. Chu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Transcriptional targeting by microRNA-Polycomb complexes: A novel route in cell fate determination
- (2012) Giuseppe Zardo et al. CELL CYCLE
- A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
- (2012) U. Banerji et al. CLINICAL CANCER RESEARCH
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial
- (2012) Toshihiko Doi et al. International Journal of Clinical Oncology
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
- (2012) A. Dasari et al. INVESTIGATIONAL NEW DRUGS
- Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
- (2012) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer
- (2012) David R. Jones et al. Journal of Thoracic Oncology
- Trials with ‘epigenetic’ drugs: An update
- (2012) Angela Nebbioso et al. Molecular Oncology
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
- (2011) W. P. Yong et al. ANNALS OF ONCOLOGY
- Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
- (2011) B. Ramaswamy et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
- (2011) A R A Razak et al. BRITISH JOURNAL OF CANCER
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
- (2011) R Pili et al. BRITISH JOURNAL OF CANCER
- The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer
- (2011) Geoffrey I. Shapiro et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies
- (2011) Julie Bauman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
- (2011) Steven A. Belinsky et al. CANCER RESEARCH
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
- (2011) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
- (2011) J. Drappatz et al. JOURNAL OF NEURO-ONCOLOGY
- DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
- (2011) M. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- Epigenetic cancer therapy: rationales, targets and drugs
- (2011) M Rius et al. ONCOGENE
- A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma
- (2011) T. A. Mohammed et al. ONCOLOGIST
- Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
- (2011) Åse Bratland et al. Radiation Oncology
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
- (2010) Fang Fang et al. CANCER
- A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
- (2010) Dana Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
- (2010) N. L. Steele et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
- (2010) Peter M. Wilson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
- (2010) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study
- (2010) A. Scherpereel et al. EUROPEAN RESPIRATORY JOURNAL
- Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
- (2010) Bryan J. Schneider et al. INVESTIGATIONAL NEW DRUGS
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
- (2010) Anne Hansen Ree et al. LANCET ONCOLOGY
- A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
- (2010) Jaime Coronel et al. MEDICAL ONCOLOGY
- Epigenetic modifications in pluripotent and differentiated cells
- (2010) Alexander Meissner NATURE BIOTECHNOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
- (2009) P N Munster et al. BRITISH JOURNAL OF CANCER
- A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
- (2009) A Rocca et al. BRITISH JOURNAL OF CANCER
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
- (2009) Yutaka Fujiwara et al. CANCER SCIENCE
- Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1
- (2009) Narender Singh et al. ChemMedChem
- A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
- (2009) J. Lin et al. CLINICAL CANCER RESEARCH
- A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
- (2009) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
- (2009) A. I. Daud et al. CLINICAL CANCER RESEARCH
- Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
- (2009) P. Munster et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
- (2008) F. Braiteh et al. CLINICAL CANCER RESEARCH
- Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
- (2008) Giuseppe Leone et al. CURRENT MEDICINAL CHEMISTRY
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
- (2008) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More